Equity research analysts tracking Ocugen, Inc. throughout 2026 maintain consensus twelve-month forward-looking price targets averaging between $8.00 and $12.00 per share. These projections reflect optimistic valuations based on the potential commercial success and regulatory approval milestones of its late-stage modifier gene therapy pipeline. However, financial forecasters continually emphasize that these target estimates remain highly speculative, depending entirely on positive clinical data readouts, partnership announcements, and ongoing capital management execution.